Mark A. Oyama

Jul 13, 2024 | onlinelibrary.wiley.com | Jonathan Elliott |Mark A. Oyama

1 INTRODUCTION Sodium glucose transporter type 2 (SGLT2) inhibitors are a new class of drug introduced in human medicine to aid control of blood glucose in diabetic patients with the first drug being approved by FDA in 2013. It soon became clear from the clinical trials that these drugs did far more than assist in blood glucose control.